BioCina
Jan Bekker is an experienced professional in the biotechnology and pharmaceuticals fields, currently serving as Vice President of Business Development and Commercial Operations at BioCina since October 2021, where responsibilities include overseeing technical aspects of new development and manufacturing programs. Previous roles at BioCina involved Director-level positions focusing on strategy and business development within a CDMO specializing in recombinant biotherapeutics. Prior to BioCina, Jan Bekker held leadership positions at Pfizer and Hospira, emphasizing strategic development and analytical project management. Academic qualifications include a PhD in Synthetic Biology and an MBA from UNSW Business School, alongside various degrees in biochemistry and related sciences from several esteemed institutions. Additionally, Jan Bekker has contributed to the scientific community as a member of the Board of Advisors at the University of Adelaide.
This person is not in any teams
BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA and Health Canada. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award. Learn more at https://biocina.com.